

# Complement in the Pathophysiology of the Antiphosph

Frontiers in Immunology

10, 449

DOI: [10.3389/fimmu.2019.00449](https://doi.org/10.3389/fimmu.2019.00449)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Type I interferon gene expression in antiphospholipid syndrome: Pathogenetic, clinical and therapeutic implications. <i>Journal of Autoimmunity</i> , 2019, 104, 102311.	6.5	26
2	Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics. <i>Transfusion Medicine Reviews</i> , 2019, 33, 256-265.	2.0	46
3	Complement and Coagulation: Cross Talk Through Time. <i>Transfusion Medicine Reviews</i> , 2019, 33, 199-206.	2.0	48
4	Is there a role for immunosuppression in antiphospholipid syndrome?. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 426-432.	2.5	22
5	The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. <i>Blood Reviews</i> , 2020, 39, 100610.	5.7	85
6	Autoantibodies in connective tissue disease. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101462.	3.3	17
7	Managing pregnancy-associated clinical emergencies in systemic lupus erythematosus: a case-based approach. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 5-22.	3.0	3
8	The Weight of IgA Anti-β <sub>2</sub> glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8972.	4.1	23
9	Understanding and Preventing Placenta-Mediated Pregnancy Complications. <i>Hamostaseologie</i> , 2020, 40, 356-363.	1.9	12
10	Management of Non-criteria Manifestations in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2020, 22, 51.	4.7	22
11	Immunometabolic Status of COVID-19 Cancer Patients. <i>Physiological Reviews</i> , 2020, 100, 1839-1850.	28.8	20
12	Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. <i>Nature Reviews Rheumatology</i> , 2020, 16, 581-589.	8.0	203
13	Management of anticoagulant-refractory thrombotic antiphospholipid syndrome. <i>Lancet Haematology</i> , 2020, 7, e613-e623.	4.6	6
14	Autoantibodies specific for C1q, C3b, β <sub>2</sub> -glycoprotein 1 and annexins may amplify complement activity and reduce apoptosis-mediated immune suppression. <i>Medical Hypotheses</i> , 2020, 144, 110286.	1.5	5
15	Acute dilated cardiomyopathy in the setting of catastrophic antiphospholipid syndrome and thrombotic microangiopathy: A case series and review. <i>EJHaem</i> , 2020, 1, 44-50.	1.0	1
16	NETs in APS: Current Knowledge and Future Perspectives. <i>Current Rheumatology Reports</i> , 2020, 22, 67.	4.7	31
17	16th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. <i>Lupus</i> , 2020, 29, 1594-1600.	1.6	26
18	Antiphospholipid syndrome. <i>Translational Research</i> , 2020, 225, 70-81.	5.0	44

#	ARTICLE	IF	CITATIONS
19	Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature. <i>Lupus</i> , 2020, 29, 631-639.	1.6	13
20	Pediatric APS: State of the Art. <i>Current Rheumatology Reports</i> , 2020, 22, 9.	4.7	19
21	Circulating proteomic signature for detection of biomarkers in bladder cancer patients. <i>Scientific Reports</i> , 2020, 10, 10999.	3.3	28
22	The antiphospholipid syndrome "often overlooked cause of vascular occlusions?". <i>Journal of Internal Medicine</i> , 2020, 287, 349-372.	6.0	27
23	Antiphospholipid syndrome: a clinical perspective. <i>Chinese Medical Journal</i> , 2020, 133, 929-940.	2.3	22
24	Clinical features associated with pregnancy outcomes in women with positive antiphospholipid antibodies and previous adverse pregnancy outcomes: a real-world prospective study. <i>Clinical Rheumatology</i> , 2021, 40, 193-204.	2.2	14
25	Complement as a Therapeutic Target in Systemic Autoimmune Diseases. <i>Cells</i> , 2021, 10, 148.	4.1	18
26	Clinical characteristics, inflammation and coagulation status in patients with immunological disease-related chronic cerebrospinal venous insufficiency. <i>Annals of Translational Medicine</i> , 2021, 9, 236-236.	1.7	3
27	Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?. <i>Biomedicines</i> , 2021, 9, 132.	3.2	11
29	Understanding the Pathophysiology of Thrombotic APS through Animal Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2588.	4.1	9
30	Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia in Association with Antiphospholipid Syndrome. <i>Acta Haematologica</i> , 2021, 144, 1-4.	1.4	2
31	New insights into the pathogenic mechanisms and treatment of arterial thrombosis in antiphospholipid syndrome. <i>European Journal of Rheumatology</i> , 2021, 8, 93-99.	0.6	6
32	Complement, inflammation and thrombosis. <i>British Journal of Pharmacology</i> , 2021, 178, 2892-2904.	5.4	39
33	Bleeding in Patients with Antiphospholipid Antibodies. , 0, , .		0
34	Is complement the culprit behind COVID-19 vaccine-related adverse reactions?. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	25
35	A hitchhiker's guide through the COVID-19 galaxy. <i>Clinical Immunology</i> , 2021, 232, 108849.	3.2	3
36	Expert Perspective: Management of Microvascular and Catastrophic Antiphospholipid Syndrome. <i>Arthritis and Rheumatology</i> , 2021, 73, 1780-1790.	5.6	16
37	Cutaneous Pathology of COVID-19 as a Window into Immunologic Mechanisms of Disease. <i>Dermatologic Clinics</i> , 2021, 39, 533-543.	1.7	6

#	ARTICLE	IF	CITATIONS
38	Crosstalk between inflammation and coagulation: Focus on pregnancy related complications. Thrombosis Update, 2021, 5, 100072.	0.9	0
39	OUP accepted manuscript. Laboratory Medicine, 2021, , .	1.2	1
40	Endothelial and Complement Activation As Predictors of Survival in Adult Allogeneic Hematopoietic Cell Transplantation. HemaSphere, 2021, 5, e487.	2.7	22
41	Complementopathies and precision medicine. Journal of Clinical Investigation, 2020, 130, 2152-2163.	8.2	70
43	Complements and Catastrophe: How Complement Activation Affects Clinical Phenotype in Antiphospholipid Syndrome. , 2020, 17, .		0
45	Retinal Artery Occlusion. , 2020, , 1-21.		0
46	Effects of anti-Beta 2-Glycoprotein 1 antibodies and its association with pregnancy-related morbidity in antiphospholipid syndrome. American Journal of Reproductive Immunology, 2022, 87, e13509.	1.2	9
47	COVID-19, Pre-Eclampsia, and Complement System. Frontiers in Immunology, 2021, 12, 775168.	4.8	19
48	Eculizumab for refractory thrombosis in antiphospholipid syndrome. Blood Advances, 2022, 6, 1271-1277.	5.2	9
49	Clinical Management of Thrombotic Antiphospholipid Syndrome. Journal of Clinical Medicine, 2022, 11, 735.	2.4	11
50	Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review. Journal of Clinical Medicine, 2022, 11, 675.	2.4	33
51	Risk of Thrombosis, Pregnancy Morbidity or Death in Antiphospholipid Syndrome. Frontiers in Cardiovascular Medicine, 2022, 9, 852777.	2.4	8
52	The complement system and autoimmune diseases. Chronic Diseases and Translational Medicine, 2022, 8, 184-190.	1.2	3
53	Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis. Journal of Autoimmunity, 2022, 128, 102813.	6.5	37
54	COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION). Lupus, 2021, 30, 2276-2285.	1.6	21
55	Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. Paediatric Drugs, 2022, 24, 13-27.	3.1	5
56	Retinal Artery Occlusion. , 2022, , 3063-3083.		0
57	Thrombophilia, antiphospholipid antibodies, and anticoagulation in recurrent implantation failure. , 2022, , 317-330.		0

#	ARTICLE	IF	CITATIONS
58	Protection by hydroxychloroquine prevents placental injury in obstetric antiphospholipid syndrome. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 4357-4370.	3.6	10
59	Antiphospholipid antibodies and vitamin D deficiency in COVID-19 infection with and without venous or arterial thrombosis: A pilot case-control study. <i>PLoS ONE</i> , 2022, 17, e0269466.	2.5	3
60	Thrombotic Thrombocytopenic Purpura, Atypical Hemolytic Uremic Syndrome, and Spectrum of Thrombotic Microangiopathy. , 2022, , 595-635.		0
61	Thrombotic Thrombocytopenic Purpura, Atypical Hemolytic Uremic Syndrome, and Spectrum of Thrombotic Microangiopathy. , 2022, , 1-42.		0
62	Neurologic Manifestations of Catastrophic Antiphospholipid Syndrome. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 589-600.	4.2	3
63	Contributions of animal models to mechanistic understandings of antibody-dependent disease and roles of the amplification loop. <i>Immunological Reviews</i> , 0, , .	6.0	3
64	Emerging Therapies in Antiphospholipid Syndrome. <i>Transfusion Medicine Reviews</i> , 2022, 36, 195-203.	2.0	1
65	Hematological manifestations of antiphospholipid syndrome: Going beyond thrombosis. <i>Blood Reviews</i> , 2023, 58, 101015.	5.7	5
66	Phytochemicals and Biological Activities of Burdock ( <i>Arctium lappa</i> L.) Extracts: A Review. <i>Chemistry and Biodiversity</i> , 2022, 19, .	2.1	4
67	Immunological parameters of recurrent miscarriages among women in Thi-Qar province. <i>Journal of Medicine and Life</i> , 2022, 15, 635-639.	1.3	1
68	B-Cells and BAFF in Primary Antiphospholipid Syndrome, Targets for Therapy?. <i>Journal of Clinical Medicine</i> , 2023, 12, 18.	2.4	7
69	Whole blood transcriptome identifies interferon-regulated genes as key drivers in thrombotic primary antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , 2023, 134, 102978.	6.5	6
70	Application of anti-Xa assay in monitoring unfractionated heparin therapy in contemporary antithrombotic management. <i>Expert Review of Hematology</i> , 2023, 16, 1-8.	2.2	0
71	Mechanisms of Thrombosis in Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 444-452.	2.7	6
72	Complement biology for hematologists. <i>American Journal of Hematology</i> , 2023, 98, .	4.1	6
73	Low complement levels are related to poor obstetric outcomes in women with obstetric antiphospholipid syndrome. The EUROAPS Registry Study Group. <i>Placenta</i> , 2023, 136, 29-34.	1.5	4
74	Anti-Neutrophil Extracellular Trap Antibodies in Antiphospholipid Antibody-Positive Patients: Results From the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository. <i>Arthritis and Rheumatology</i> , 2023, 75, 1407-1414.	5.6	15
75	Hospitalized patients with positive antiphospholipid antibodies who have low complement levels are at increased risk for death—a retrospective cohort study. <i>Lupus</i> , 0, , 096120332311640.	1.6	0

#	ARTICLE	IF	CITATIONS
76	Heart Valve Surgery in Antiphospholipid Syndrome Patientsâ€™ Morbidity and Mortality. <i>Life</i> , 2023, 13, 891.	2.4	0
77	Role of Î²2â€™glycoprotein I in the pathogenesis of the antiphospholipid syndrome. <i>Rheumatology &amp; Autoimmunity</i> , 0, , .	0.8	0
78	Complement therapeutics are coming of age in rheumatology. <i>Nature Reviews Rheumatology</i> , 2023, 19, 470-485.	8.0	2
79	Platelets and the Lectin Pathway of Complement Activation in Patients with Systemic Lupus Erythematosus or Antiphospholipid Syndrome. <i>TH Open</i> , 2023, 07, e155-e167.	1.4	2
81	Evaluating complement dysregulation in livedoid vasculopathy using a functional assay. <i>Blood Advances</i> , 0, , .	5.2	0
82	Rare variants in complement system genes associate with endothelial damage after pediatric allogeneic hematopoietic stem cell transplantation. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
83	Complement biomarkers in the antiphospholipid syndrome â€™ Approaches to quantification and implications for clinical management. <i>Clinical Immunology</i> , 2023, 257, 109828.	3.2	0
84	An immunogenomic exome landscape of triple positive primary antiphospholipid patients. <i>Genes and Immunity</i> , 2024, 25, 108-116.	4.1	0
85	Anticoagulant and non-anticoagulant therapy in thrombotic antiphospholipid syndrome: old drugs and new treatment targets. <i>Rheumatology</i> , 2024, 63, SI96-SI106.	1.9	1
86	Single-cell transcriptome analyses reveal disturbed decidual homeostasis in obstetric antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2024, 83, 624-637.	0.9	0
87	Anesthetic Management of a Jehovahâ€™s Witness Patient for Coronary Artery Bypass Grafting With Antiphospholipid Antibody Syndrome and Renal Transplant. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 0, , .	1.0	0